Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Atrium Innovations has announced that following a US court decision, the company has received approval to sell its enzyme supplement Wobenzym in the US.
Subscribe to our email newsletter
Marlyn Nutraceuticals has been ordered by the US District Court to immediately stop using the Wobenzym trademark and selling products under this name.
Wobenzym was initially developed by Mucos Pharma, a company acquired by Atrium in July 2007. Wobenzym is an enzyme-based product well known for its numerous benefits for the health of joints, muscles and tendons as well as for the immune system.
Pierre Fitzgibbon, president and CEO of Atrium Innovations, said: “We are very pleased with this court ruling, which will allow us to start selling Wobenzym in the US immediately and with no restrictions. This high-quality product, sold as an enzyme supplement in the US offers a natural solution to very common conditions such as joint and muscle discomfort.”